Albireo Pharma Performance
| ALBODelisted Stock | USD 44.15 0.75 1.67% |
The firm shows a Beta (market volatility) of 0.0955, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Albireo Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Albireo Pharma is expected to be smaller as well. Albireo Pharma right now shows a risk of 0.0%. Please confirm Albireo Pharma value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to decide if Albireo Pharma will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Albireo Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy fundamental drivers, Albireo Pharma is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 251.3 M | |
| Total Cashflows From Investing Activities | 102.9 M |
Albireo |
Albireo Pharma Relative Risk vs. Return Landscape
If you would invest 4,415 in Albireo Pharma on January 25, 2024 and sell it today you would earn a total of 0.00 from holding Albireo Pharma or generate 0.0% return on investment over 90 days. Albireo Pharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Albireo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Albireo Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Albireo Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Albireo Pharma, and traders can use it to determine the average amount a Albireo Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ALBO |
Based on monthly moving average Albireo Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Albireo Pharma by adding Albireo Pharma to a well-diversified portfolio.
Albireo Pharma Fundamentals Growth
Albireo Stock prices reflect investors' perceptions of the future prospects and financial health of Albireo Pharma, and Albireo Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Albireo Stock performance.
| Return On Equity | -0.93 | |||
| Return On Asset | -0.25 | |||
| Profit Margin | (2.29) % | |||
| Operating Margin | (2.15) % | |||
| Current Valuation | 259.98 M | |||
| Shares Outstanding | 20.74 M | |||
| Price To Earning | (4.16) X | |||
| Price To Book | 4.30 X | |||
| Price To Sales | 7.35 X | |||
| Revenue | 40.58 M | |||
| EBITDA | (19.82 M) | |||
| Cash And Equivalents | 180.97 M | |||
| Cash Per Share | 9.23 X | |||
| Total Debt | 10 M | |||
| Debt To Equity | 0.18 % | |||
| Book Value Per Share | 4.84 X | |||
| Cash Flow From Operations | (107.56 M) | |||
| Earnings Per Share | (6.66) X | |||
| Total Asset | 302.05 M | |||
| Retained Earnings | (171.75 M) | |||
| Current Asset | 28.84 M | |||
| Current Liabilities | 2.07 M | |||
About Albireo Pharma Performance
To evaluate Albireo Pharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Albireo Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Albireo Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Albireo Pharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Albireo's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. Albireo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 130 people.Things to note about Albireo Pharma performance evaluation
Checking the ongoing alerts about Albireo Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Albireo Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Albireo Pharma is not yet fully synchronised with the market data | |
| Albireo Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 40.58 M. Net Loss for the year was (34.03 M) with profit before overhead, payroll, taxes, and interest of 39.22 M. | |
| Albireo Pharma currently holds about 180.97 M in cash with (107.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.23. | |
| Over 96.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Albireo Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Albireo Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Albireo Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Albireo Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Albireo Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Albireo Pharma's stock. These opinions can provide insight into Albireo Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Albireo Stock
If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |